Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 6 recruiting now full pipeline

Acute Coronary Syndrome: full-pipeline trial registry

6 of 41 indexed Acute Coronary Syndrome trials are currently recruiting.

Corpus placement: #357 of 28,707 conditions by registered trial count.

41 US clinical trials · 6 currently recruiting · #357 of 28,707 conditions by registered trial count

Acute Coronary Syndrome: 41 US clinical trials tracked, 6 recruiting.

Acute Coronary Syndrome is the subject of 41 registered US clinical trials on ClinicalTrials.gov, 6 of them currently open to new participants. 7 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Hennepin Healthcare Research Institute, running 4 of these trials.

Enrollment posture brief

Registry condition acute-coronary-syndrome

OPEN 6 | RECR 15% | LATE 7 | EARLY 8 | RANK #357 | SPON 4

Nearest open-share peer: Dry Eye Disease (15% recruiting · 34 trials)

Gastroesophageal Junction Ad58.5%Depression, Anxiety51.2%Healthy Aging48.8%Dyslipidemia17.1%Acute Coronary Syndrome (thi…15%
Open-enrollment share among volume-matched conditions near Acute Coronary Syndrome

Acute Coronary Syndrome lists 6 open slots (15% of 41 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Acute Coronary Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Acute Coronary Syndrome is recruiting below its size-band peers.

    6 of 41 indexed trials (14.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Acute Coronary Syndrome trials is spread across many organizations.

    Hennepin Healthcare Research Institute accounts for 4 of 41 trials (9.8%). 30 distinct sponsors appear on at least one study for this condition label.

  3. Typical Acute Coronary Syndrome enrolment sits around 500 participants.

    Median target enrolment is 500 among the 41 trials that report a genuine target (sentinel values excluded). 9 of those (22%) plan for fewer than 100 participants.

  4. Acute Coronary Syndrome splits between interventional and observational designs.

    27 interventional and 14 observational studies make up this index (65.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 13Phase 25Phase 36Phase 41

Open and recent trials

41 total, page 1 of 1

RECRUITING Phase 3 2,000 participants

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

DalCor Pharmaceuticals

NCT05918861

RECRUITING Phase 2 1,000 participants

A Polypill for Acute Coronary Syndrome

University of Texas Southwestern Medical Center

NCT07032389

RECRUITING 500 participants

AngelMed Guardian® System PMA Post Approval Study

Angel Medical Systems

NCT05412927

RECRUITING NA 280 participants

Positive Emotions Following Acute Cardiac Events

Massachusetts General Hospital

NCT05412862

RECRUITING 200 participants

Left Ventricular Physiological Effects of Veno-Arterial Extracorporeal Membrane Oxygenation Support During Cardiogenic Shock

University of Minnesota

NCT05426083

RECRUITING 150 participants

A Prospective Research Investigation of Ischemia Using MCG

SB Technology

NCT06481943

ACTIVE NOT RECRUITING Phase 3 14,194 participants

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

Janssen Research & Development

NCT05754957

ACTIVE NOT RECRUITING 2,000 participants

COmparisoN of High-sensitivity Cardiac TRoponin I and T ASsays Trial

Hennepin Healthcare Research Institute

NCT03214029

ACTIVE NOT RECRUITING 1,500 participants

MERITnI - Mindray-hs-cTnI Assay: Analytical and Clinical Evaluation for the Diagnosis and RIsk AssessmenT of Myocardial InfarctIon.

Hennepin Healthcare Research Institute

NCT05853042

ACTIVE NOT RECRUITING NA 1,203 participants

LEADERS FREE II: BioFreedom™ Pivotal Study

Biosensors Europe

NCT02843633

ACTIVE NOT RECRUITING NA 233 participants

Post Acute Cardiac Event Smoking (PACES) Study

Hennepin Healthcare Research Institute

NCT03413423

ACTIVE NOT RECRUITING 215 participants

Enhancing Rural Health Via Cardiovascular Telehealth for Rural Patients Implementation (E-VICTORS)

Wake Forest University Health Sciences

NCT04617834

ACTIVE NOT RECRUITING Phase 2 70 participants

Online Tai Chi Plus Fitbit After ACS

Beth Israel Deaconess Medical Center

NCT05699642

ACTIVE NOT RECRUITING NA 60 participants

Healthy Heart Habits-2

The Miriam Hospital

NCT06440278

ACTIVE NOT RECRUITING NA 12 participants

OPTIMIZE Sirolimus-Eluting Coronary Stent Systems Pharmacokinetics (PK) Study

Svelte Medical Systems

NCT03716102

COMPLETED Phase 3 18,624 participants

A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome

AstraZeneca

NCT00391872

COMPLETED Phase 3 15,526 participants

An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

NCT00809965

COMPLETED 14,717 participants

HEART Pathway Implementation

Wake Forest University Health Sciences

NCT02056964

COMPLETED 12,227 participants

Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome

Eli Lilly and Company

NCT01088503

COMPLETED Phase 3 6,068 participants

Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)

Sanofi

NCT01147250

COMPLETED 6,000 participants

ECG Methods for the Prompt Identification of Coronary Events

University of Pittsburgh

NCT04237688

COMPLETED NA 2,800 participants

GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety

Accumetrics

NCT00645918

COMPLETED Phase 2 2,753 participants

Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes

Takeda

NCT00677053

COMPLETED 1,949 participants

5th Generation cTnT in ED ACS

Columbia University

NCT03590535

COMPLETED NA 862 participants

Pharmacist Intervention to Decrease Medication Errors in Heart Disease Patients (The PILL-CVD Study)

Vanderbilt University Medical Center

NCT00632021

COMPLETED Phase 2 526 participants

A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation

GlaxoSmithKline

NCT00910962

COMPLETED 511 participants

PARA-HEART Pilot Implementation

Wake Forest University Health Sciences

NCT02709135

COMPLETED Phase 2 510 participants

Safety and Efficacy Iodofiltic Acid I 123 in the Treatment of Acute Coronary Syndrome

Molecular Insight Pharmaceuticals

NCT00514501

COMPLETED NA 509 participants

Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention

University of Pennsylvania

NCT02508116

COMPLETED Phase 3 400 participants

Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome

Novartis Pharmaceuticals

NCT04873934

COMPLETED 368 participants

Rule Out Myocardial Infarction by Computer Assisted Tomography

Massachusetts General Hospital

NCT00990262

COMPLETED NA 290 participants

Pragmatic Collaborative Care for Cardiac Inpatients With Depression or Anxiety

Massachusetts General Hospital

NCT03118752

COMPLETED Phase 1 150 participants

Comparison of Depression Interventions After Acute Coronary Syndrome

Columbia University

NCT01032018

COMPLETED NA 110 participants

Cost Comparison of Cardiac Magnetic Resonance Imaging (MRI) Use in Emergency Department (ED) Patients With Chest Pain

Wake Forest University Health Sciences

NCT00678639

COMPLETED 101 participants

Magnetocardiography Using a Novel Analysis System (Cardioflux) in the Evaluation of Emergency Department Observation Unit Chest Pain Patients

Genetesis

NCT03255772

COMPLETED Phase 4 77 participants

The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel

Medstar Health Research Institute

NCT01365221

COMPLETED NA 60 participants

Mind-body Interventions in Cardiac Patients

Massachusetts General Hospital

NCT01270568

COMPLETED Phase 1 56 participants

A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin

GlaxoSmithKline

NCT01756495

COMPLETED 40 participants

Apixaban + DAPT in Lowering Platelet Reactivity and Thrombin Generation

CirQuest Labs

NCT03746782

COMPLETED NA 14 participants

HeartHome: A Nurse-Driven, Home-Based Cardiac Rehabilitation Program

University of North Carolina, Chapel Hill

NCT04131816

COMPLETED Phase 1 8 participants

Healthy Heart Habits

Hennepin Healthcare Research Institute

NCT04158219

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 5
Phase 3 6
Phase 4 1

Named interventions

Most-linked intervention names on Acute Coronary Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
4 trials
Sertraline, citalopram, or bupropion Drug
1 trials
HeartHome Behavioral
1 trials
GW856553 Drug
1 trials
ADP receptor inhibitors Drug
1 trials
5th Gen cTnT Diagnostic test
1 trials
4th Gen cTnT Diagnostic test
1 trials
CYP2C19 genotyping Genetic
1 trials

US sites by state

Facility locations filed on Acute Coronary Syndrome trials. A trial with sites in several states counts in each.

California 12 trials
Arizona 11 trials
Alabama 11 trials
Minnesota 10 trials
Florida 9 trials
North Carolina 7 trials
Massachusetts 7 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Acute Coronary Syndrome page

41 registered trials, 6 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Acute Coronary Syndrome condition card totals 41 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.